{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:29:19Z","timestamp":1794266959976,"version":"4.9.0"},"reference-count":46,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Infections caused by MBL-producing Gram-negative bacterial pathogens have disseminated worldwide and are associated with considerable morbidity and mortality. We evaluated the published clinical evidence on the use of various antibiotics for the treatment of patients with such infections. The available data suggest the consideration of the new antibiotics cefiderocol and aztreonam-avibactam for the treatment of patients with infections caused by MBL-producing Gram-negative bacterial pathogens. However, their considerable cost and limited availability hinder their use. Also, the combination of ceftazidime-avibactam and aztreonam has been occasionally used, especially when there was an unavailability of aztreonam-avibactam. Additionally, old antibiotics such as colistin and fosfomycin, especially in combination antimicrobial therapy, may be considered for the treatment of patients with such infections. The relevant clinical data on the use of tigecycline and aminoglycosides for infections caused by MBL-producing pathogens are limited. Thus, the evaluation of the published evidence suggests the best treatment options for the treatment of patients with such infections at present. Also, the limited available data highlight the need for dissemination of the already acquired clinical experience and the conduct of new studies examining currently available antibiotics, as well as investigational antimicrobial agents for the treatment of patients with infections caused by MBL-producing Gram-negative bacterial pathogens.<\/jats:p>","DOI":"10.3390\/antibiotics14090894","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T09:51:21Z","timestamp":1757065881000},"page":"894","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antibiotics for the Treatment of Patients with Metallo-\u03b2-Lactamase (MBL)-Producing Gram-Negative Bacterial Infections"],"prefix":"10.3390","volume":"14","author":[{"given":"Matthew E.","family":"Falagas","sequence":"first","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece"},{"name":"School of Medicine, European University Cyprus, 6 Diogenous Str., 2404 Nicosia, Cyprus"},{"name":"Department of Medicine, Tufts University School of Medicine, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios S.","family":"Kontogiannis","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9047-7926","authenticated-orcid":false,"given":"Dimitrios","family":"Ragias","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos A.","family":"Kakoullis","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus, 6 Diogenous Str., 2404 Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Falagas, M.E., Kontogiannis, D.S., Zidrou, M., Filippou, C., and Tansarli, G.S. (2025). Global Epidemiology and Antimicrobial Resistance of Metallo-\u03b2-Lactamase (MBL)-Producing Acinetobacter Clinical Isolates: A Systematic Review. Pathogens, 14.","DOI":"10.3390\/pathogens14060557"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/13543784.2025.2532443","article-title":"Antibiotics and Non-Traditional Antimicrobial Agents for Pseudomonas Aeruginosa in Clinical Phases 1, 2, and 3 Trials","volume":"34","author":"Romanos","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Taheri, Y., Jokovi\u0107, N., Vitorovi\u0107, J., Grundmann, O., Maroyi, A., and Calina, D. (2021). The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.578823"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37201\/req\/s02.02.2022","article-title":"Mechanism of Action of Cefiderocol","volume":"35","author":"Soriano","year":"2022","journal-title":"Rev. Esp. Quimioter"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the Treatment of Infections Due to Metallo-B-Lactamase\u2013Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and Safety of Cefiderocol or Best Available Therapy for the Treatment of Serious Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria (CREDIBLE-CR): A Randomised, Open-Label, Multicentre, Pathogen-Focused, Descriptive, Phase 3 Trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"El Ghali, A., Kunz Coyne, A.J., Lucas, K., Tieman, M., Xhemali, X., Lau, S., Iturralde, G., Purdy, A., Holger, D.J., and Garcia, E. (2024). Cefiderocol: Early Clinical Experience for Multi-Drug Resistant Gram-Negative Infections. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.03108-23"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kirkegaard-Biosca, C., del Barrio-Tofi\u00f1o, E., Villamar\u00edn, M., Larrosa, N., Campany, D., Gonz\u00e1lez-L\u00f3pez, J.J., Ferrer, R., Vi\u00f1ado, B., Dom\u00e9nech, L., and Sellar\u00e8s-Nadal, J. (2024). Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics, 13.","DOI":"10.3390\/antibiotics13090874"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/cid\/ciad725","article-title":"Clinical Features and Outcomes of Infections Caused by Metallo-\u03b2-Lactamase\u2013Producing Enterobacterales: A 3-Year Prospective Study From an Endemic Area","volume":"78","author":"Falcone","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"ofae631.1699","DOI":"10.1093\/ofid\/ofae631.1699","article-title":"P-1531. Two against One: Ceftazidime-Avibactam plus Aztreonam vs Cefiderocol in the Treatment of Metallo-Beta-Lactamase-Producing Bacterial Infections","volume":"12","author":"Harris","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_11","unstructured":"Mezzadri, L., Ricci, E., Merli, M., Corti, N., Faltoni, M., Bandera, A., Maggi, P., Bartoletti, M., Mastroianni, M., and Rusconi, S. (2025, January 11\u201315). Ceftazidime-Avibactam plus Aztreonam versus Cefiderocol in the Treatment of Infections Caused by Metallo-\u03b2 Lactamase-Producing Microorganisms: Real-Word Data from the Italian Cohort SUSANA. Proceedings of the ESCMID Global 2025. Congress of the European Society of\u2028 Clinical Microbiology and Infectious Diseases, Vienna, Austria."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wicky, P.-H., Poiraud, J., Alves, M., Patrier, J., d\u2019Humi\u00e8res, C., L\u00ea, M., Kramer, L., de Montmollin, \u00c9., Massias, L., and Armand-Lef\u00e8vre, L. (2023). Cefiderocol Treatment for Severe Infections Due to Difficult-to-Treat-Resistant Non-Fermentative Gram-Negative Bacilli in ICU Patients: A Case Series and Narrative Literature Review. Antibiotics, 12.","DOI":"10.3390\/antibiotics12060991"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"dlae015","DOI":"10.1093\/jacamr\/dlae015","article-title":"Successful Outpatient Parenteral Antibiotic Therapy with Cefiderocol for Osteomyelitis Caused by Multi-Drug Resistant Gram-Negative Bacteria: A Case Report","volume":"6","author":"Schellong","year":"2023","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2147\/IDR.S485450","article-title":"Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. Pneumoniae NDM, OXA48 Intraabdominal Infection","volume":"17","author":"Tarski","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14787210.2025.2473047","article-title":"Past, Present, and Future Perspectives on Aztreonam and Avibactam","volume":"23","author":"Bush","year":"2025","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_16","unstructured":"(2025, July 16). Pfizer A Prospective, Randomized, Open-Label, Comparative Study to Assess the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (Atm-Avi) and Best Available Therapy for the Treatment of Serious Infections Due to Multi-Drug Resistant Gram-Negative Bacteria Producing Metallo -\u03b2-Lactamase (MBL). Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004544-38\/results."},{"key":"ref_17","unstructured":"European Medicines Agency (2025, June 20). Emblaveo. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/emblaveo."},{"key":"ref_18","unstructured":"Pfizer Limited (2025, June 20). Emblaveo 1.5 g\/0.5 g powder for concentrate for solution for infusion. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/15895\/smpc."},{"key":"ref_19","unstructured":"(2025, June 20). Emblaveo (Aztreonam and Avibactam) [Prescribing Information]. AbbVie Inc; U.S. Food and Drug Administration: North Chicago, IL, USA, 2025. EMBLAVEO (aztreonam and avibactam) for injection, for intravenous use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217906Orig1s000lbl.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of Ceftazidime-Avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-\u03b2-Lactamase\u2013Producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"780","DOI":"10.5005\/jp-journals-10071-23863","article-title":"Clinical Outcome of Patients on Ceftazidime\u2013Avibactam and Combination Therapy in Carbapenem-Resistant Enterobacteriaceae","volume":"25","author":"Nagvekar","year":"2021","journal-title":"Indian J. Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e13510","DOI":"10.1111\/tid.13510","article-title":"Treatment of Invasive IMP-4 Enterobacter Cloacae Infection in Transplant Recipients Using Ceftazidime\/Avibactam with Aztreonam: A Case Series and Literature Review","volume":"23","author":"Cairns","year":"2020","journal-title":"Transpl. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Alghoribi, M.F., Alqurashi, M., Okdah, L., Alalwan, B., AlHebaishi, Y.S., Almalki, A., Alzayer, M.A., Alswaji, A.A., Doumith, M., and Barry, M. (2021). Successful Treatment of Infective Endocarditis Due to Pandrug-Resistant Klebsiella Pneumoniae with Ceftazidime-Avibactam and Aztreonam. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-89255-8"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"105842","DOI":"10.1016\/j.ijantimicag.2019.10.023","article-title":"Successful Treatment of Septic Shock Due to NDM-1-Producing Klebsiella Pneumoniae Using Ceftazidime\/Avibactam Combined with Aztreonam in Solid Organ Transplant Recipients: Report of Two Cases","volume":"55","author":"Benchetrit","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e02463-18","DOI":"10.1128\/AAC.02463-18","article-title":"Successful Treatment of Bacteremia Due to NDM-1-Producing Morganella Morganii with Aztreonam and Ceftazidime-Avibactam Combination in a Pediatric Patient with Hematologic Malignancy","volume":"63","author":"Hobson","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Perrotta, F., and Perrini, M.P. (2021). Successful Treatment of Klebsiella Pneumoniae NDM Sepsis and Intestinal Decolonization with Ceftazidime\/Avibactam Plus Aztreonam Combination in a Patient with TTP Complicated by SARS-CoV-2 Nosocomial Infection. Medicina, 57.","DOI":"10.3390\/medicina57050424"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/jac\/dkz495","article-title":"Successful Rescue Treatment of Sepsis Due to a Pandrug-Resistant, NDM-Producing Klebsiella Pneumoniae Using Aztreonam Powder for Nebulizer Solution as Intravenous Therapy in Combination with Ceftazidime\/Avibactam","volume":"75","author":"Sieswerda","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/ajt.15136","article-title":"Transplant Tourism Complicated by Life-Threatening New Delhi Metallo-\u03b2-Lactamase-1 Infection","volume":"19","author":"Stewart","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijid.2021.05.085","article-title":"Combination of Aztreonam, Ceftazidime\u2013Avibactam and Amikacin in the Treatment of VIM-1 Pseudomonas Aeruginosa ST235 Osteomyelitis","volume":"108","author":"Mularoni","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/ejhpharm-2021-002772","article-title":"Successful Treatment of Verona Integron-Encoded Metallo-\u03b2-Lactamase-Producing Klebsiella Pneumoniae Infection Using the Combination of Ceftazidime\/Avibactam and Aztreonam","volume":"29","author":"Bejarano","year":"2022","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Andrade, F.F., Silva, D., Rodrigues, A., and Pina-Vaz, C. (2020). Colistin Update on Its Mechanism of Action and Resistance, Present and Future Challenges. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111716"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/0972-5229.56048","article-title":"Colistin and Polymyxin B: A Re-Emergence","volume":"13","author":"Gupta","year":"2009","journal-title":"Indian J. Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Shao, Z., Lu, L., Tang, S., Shi, K., Gong, F., and Liu, J. (2023). Ceftazidime\/Avibactam Combined with Colistin: A Novel Attempt to Treat Carbapenem-Resistant Gram-Negative Bacilli Infection. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08715-w"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/cid\/ciae197","article-title":"Fosfomycin as a Potential Therapeutic Option in Nonsevere Infections Caused by Metallo-\u03b2-Lactamase\u2013Producing Enterobacterales: Need for Evidence","volume":"80","author":"Falcone","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.26.8.1099","article-title":"Tigecycline: First of a New Class of Antimicrobial Agents","volume":"26","author":"Rose","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/00365548.2013.861608","article-title":"Tigecycline Therapy for Infections Due to Carbapenemase-Producing Klebsiella Pneumoniae in Critically Ill Patients","volume":"46","author":"Moreno","year":"2014","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_38","first-page":"e65617","article-title":"Tigecycline-Based Regimens for Complicated Urinary Tract Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria: Case Series","volume":"16","author":"Niculae","year":"2024","journal-title":"Cureus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/milmed\/usab350","article-title":"Carbapenem-Resistant Enterobacterales Infection After Massive Blast Injury: Use of Cefiderocol Based Combination Therapy","volume":"186","author":"Carney","year":"2021","journal-title":"Mil. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mayers, D.L., Sobel, J.D., Ouellette, M., Kaye, K.S., and Marchaim, D. (2017). Aminoglycosides: Mechanisms of Action and Resistance. Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, Springer International Publishing.","DOI":"10.1007\/978-3-319-46718-4"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e243609","DOI":"10.1136\/bcr-2021-243609","article-title":"Plazomicin for the Treatment of Multidrug-resistantKlebsiella Bacteraemia in a Patient with Underlying Chronic Kidney Disease and Acute Renal Failure Requiring Renal Replacement Therapy","volume":"14","author":"Earle","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2009.03.009","article-title":"Fosfomycin for the Treatment of Infections Caused by Multidrug-Resistant Non-Fermenting Gram-Negative Bacilli: A Systematic Review of Microbiological, Animal and Clinical Studies","volume":"34","author":"Falagas","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00228-010-0794-5","article-title":"Synergy of Fosfomycin with Other Antibiotics for Gram-Positive and Gram-Negative Bacteria","volume":"66","author":"Kastoris","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/jac\/dkx049","article-title":"Activity of Cefiderocol (S-649266) against Carbapenem-Resistant Gram-Negative Bacteria Collected from Inpatients in Greek Hospitals","volume":"72","author":"Falagas","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","article-title":"Global Prevalence of Cefiderocol Non-Susceptibility in Enterobacterales, Pseudomonas Aeruginosa, Acinetobacter Baumannii, and Stenotrophomonas Maltophilia: A Systematic Review and Meta-Analysis","volume":"30","author":"Karakonstantis","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2010.03.020","article-title":"Patients Included in Randomised Controlled Trials Do Not Represent Those Seen in Clinical Practice: Focus on Antimicrobial Agents","volume":"36","author":"Falagas","year":"2010","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/9\/894\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:39:35Z","timestamp":1760035175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/9\/894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["antibiotics14090894"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14090894","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}